Our Mission
Pioneering next-generation, neoantigen-targeting engineered T cell receptor therapies for solid cancers
Neogene Therapeutics is a global, clinical-stage biotechnology company pioneering the discovery, development, and manufacturing of next-generation engineered T cell receptor (TCR) therapies targeting a broad spectrum of solid cancers.
Cancer is a genetically individual disease – no two tumors are exactly the same. Genetic changes can create neoantigens – unique targets in or on tumor cells that set them apart from healthy cells. Neogene’s novel approach delivers a tailored therapy based on neoantigen-targeting TCR genes that target neoantigens found in an individual patient’s tumor. Our proprietary TCR identification and selection platform allows us to identify neoantigen-specific TCR genes. These TCR genes are engineered into patient-derived T cells based on in-house developed T cell engineering technologies with the goal of eliciting strong and durable responses in a variety of solid tumor indications. The ability of such engineered T cells to attack a patient tumor can be further modulated through additional, targeted genetic modifications that are explored by Neogene for this purpose.
By developing a portfolio of TCRs targeting common cancer-causing mutations that result in neoantigens shared between patients as well as TCR therapies targeting neoantigens unique to a patient’s tumor, we aim to enable wider access to individualized engineered T cell therapies for a broad spectrum of cancers.
![Carsten Linnemann](https://www.neogene.com/wp-content/uploads/CarstenLinemann-square.jpg)
While engineered T cell therapies have transformed the treatment paradigm for patients with hematologic malignancies, effective T cell therapy is unavailable for solid cancers. To truly revolutionize patient outcomes, we need a new approach to effectively treat and potentially cure solid cancers. We aim to treat a wide range of patients with solid tumors by targeting neoantigens with engineered TCR therapies.
Carsten Linnemann, Ph.D., Co-Founder and Chief Executive Officer
Our History
Neogene is built on the premise of innovation and novel paradigm-changing science to enable effective T-cell therapy of solid cancers.
-
September 2018
Founded in Amsterdam, the Netherlands, by world-class cell therapy experts Ton Schumacher, Ph.D. and Carsten Linnemann, Ph.D. to advance the development of neoantigen T cell therapies.
- May 2019
- October 2020
- November 2021
-
January 2022
Secured an exclusive license with the National Cancer Institute (NCI) for a portfolio of TCRs targeting KRAS and TP53 mutations
- May 2022
- September 2018
- September 2020
-
October 2020
Announced strategic partnership with Twist Bioscience to build synthetic TCR libraries.
- May 2021
- January 2022
-
May 2022
Received approval of Clinical Trial Application for NT-125
- January 2023
-
September 2018
September 2018
Founded in Amsterdam, the Netherlands, by world-class cell therapy experts Ton Schumacher, Ph.D. and Carsten Linnemann, Ph.D. to advance the development of neoantigen T cell therapies.
-
May 2019
May 2019
Secured seed investment from Bellco Capital, TPG, Two River and Vida Ventures.
-
September 2020
September 2020
Raised $110 million Series A financing from marquee group of investors.
-
October 2020
October 2020
Announced strategic partnership with Twist Bioscience to build synthetic TCR libraries.
-
May 2021
May 2021
Established U.S. headquarters in Santa Monica, CA
-
November 2021
November 2021
Opened first clinical TCR selection facility in Amsterdam, the Netherlands
-
January 2022
January 2022
Secured an exclusive license with the National Cancer Institute (NCI) for a portfolio of TCRs targeting KRAS and TP53 mutations
-
May 2022
May 2022
Received approval of Clinical Trial Application for NT-125
-
January 2023
January 2023
Acquired by AstraZeneca
Our Team
Neogene’s leadership team is comprised of world-leading TCR experts and cell therapy industry veterans with decades of oncology knowledge and experience, who hold a deep commitment to providing innovative therapies to patients with cancer.
![Carsten Linneman](https://www.neogene.com/wp-content/uploads/Carsten-Linneman-500x500.png)
Carsten Linnemann, Ph.D.
Chief Executive Officer
![Kanti Thirumoorthy Kanti Thirumoorthy](https://www.neogene.com/wp-content/uploads/elementor/thumbs/kanti-thirumoorthy-q0qi7n8iq48n9hxkqvdgcv5yyyppnor2dsl84y9qng.png)
Kanti Thirumoorthy, Ph.D.
Senior Vice President, Technical Operations
![Gavin M. Bendle, Ph.D. Gavin M. Bendle, Ph.D.](https://www.neogene.com/wp-content/uploads/elementor/thumbs/bendle-q0qi7o6cwy9xl3w7lds2xcxfkcl2vduspx8pm88ch8.png)
Gavin M. Bendle, Ph.D.
Senior Vice President, Research and Development
![Marisa Leonard](https://www.neogene.com/wp-content/uploads/Marisa_Leonard.png)
Marisa Leonard
Vice President, Chief of Staff to the CEO and Head of Business Development
![Sanne Weijzen, Ph.D.](https://www.neogene.com/wp-content/uploads/2020/09/sanne_weijzen.png)
Sanne Weijzen, Ph.D.
Vice President, Head of Corporate Strategy and Global Operations
![Sanjeeve Bala](https://www.neogene.com/wp-content/uploads/Sanjeeve-Bala-2-500x500.png)
Sanjeeve Bala, M.D.
Senior Vice President, Regulatory Affairs
![Arianne Perez](https://www.neogene.com/wp-content/uploads/2021/05/arianne-perez-500x500.png)
Arianne Perez Garcia, Ph.D.
Senior Vice President, Translational Sciences
![Stephanie Heintz](https://www.neogene.com/wp-content/uploads/Stephanie_Heintz.png)
Stephanie Heintz, M.P.H
Executive Director, Head of Human Resources
![Celeste Chang](https://www.neogene.com/wp-content/uploads/Celeste-Chang-2.png)
Celeste Chang, M.S. Eng, MBA
Vice President, Supply Chain
![Sarah Cohen](https://www.neogene.com/wp-content/uploads/Sarah-Cohen.png)
Sarah Cohen, M.D.
Vice President, Head of Clinical Development
![Heather Francis, MSE](https://www.neogene.com/wp-content/uploads/2021/05/heather-francis.png)
Heather Francis, M.S. Chem Eng.
Vice President, Manufacturing and Facilities
![David Lund](https://www.neogene.com/wp-content/uploads/2021/10/david-lund.png)
David Lund, Ph.D.
Vice President, Intellectual Property
![Harish Mundre](https://www.neogene.com/wp-content/uploads/Harish_Mundre.png)
Harish Mundre
Vice President, Head of Information Technology
![Marianna Sabatino](https://www.neogene.com/wp-content/uploads/2021/10/marianna-sabatino.png)
Marianna Sabatino, M.D., Ph.D.
Senior Vice President, Process Development
![Sunny Xie](https://www.neogene.com/wp-content/uploads/2022/02/sunny-xie-1.png)
Sunny Xie
Vice President, Biometrics